Serum uric acid, the endothelium and hypertension: An association revisited

Journal of Human Hypertension

Volumn 21, Issue 8, 2007, Pages 591-593

  Reynolds, T ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL; URATE; URATE OXIDASE; URIC ACID;

BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FOREARM BLOOD FLOW; HEART LEFT VENTRICLE MASS; HUMAN; HYPEREMIA; HYPERTENSION; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; PREDICTION; PROGNOSIS; RISK FACTOR; SLEEP APNEA SYNDROME;

ALLOPURINOL; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; URIC ACID;

EID: 34547492289     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002239     Document Type: Note

References (24)

1. Watanabe S, Kang D-H, Feng L, Nakagawa T, Kanellis J, Lan H et al. Uric acid, hominod evolution, and the pathogenesis of salt sensitivity. Hypertension 2002; 40: 355-360.
2. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kennel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
3. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type II diabetes mellitus: The urate redox shuttle. Nutr & Metab 2004; 1: 10 doi 10.1186/1743-7075-1-10. http://www.nutritionandmetabolism.com/content/1/1/10.
4. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: A population based study. Hypertension 2005; 45:499-504.
5. Stepnowsky CJ, Nelesen RA, DeJardin D, Dimsdale JE. Socioeconomic status is associated with nocturnal blood pressure dipping. Psychosom Med 2004; 66: 651-655.
6. Ichihara A, Kaneshiro Y, Sakoda M, Hayashi M. Ambulatory blood pressure variability and brachial pulse wave velocity in untreated hypertensive patients. J Hum Hypertens 2006; 20: 529-536.
7. Henskens LH, Kroon AA, Hofman PA, Gronenschild EH, Jolles J, de Leeuw PW, VAN boXTEL mp. Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. J Hum Hypertens 2006; 20: 5-13.
8. Kotsis V, Stabouli S, Pitiraga V, Papamichael C, Toumanidis S, Zakopoulos N. Impact of gender on 24-h ambulatory blood pressure and target organ damage. J Hum Hypertens 2006; 20: 658-665.
9. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Branetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078.
10. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-1957.
11. Matsumara K, Ohtsubo T, Oniki H, Fujii K, Iida M. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J 2006; 70: 885-888.
12. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M et al. Uric acid and the development of hypertension: The normative aging study. Hypertension 2006; 48: 1031-1036.
13. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J et al. Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol 2006; 17 (4 suppl 2): S69-S73.
14. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: The SMOOTH Trial. J Hypertens 2006; 24: 837-843.
15. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: An acive component or an innocent bystander. Metab: Clin Exp 2006; 55 1293-1301.
16. Onat A, Uyarel H, Hergenc G, Karabulat A, Albayrak S, Sari I et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006; 19: 1055-1062.
17. Coutinho T, Turner ST, Kullo IJ. Serum uric acid is associated with microvascular function in hypertensive individuals. J Human Hypertens 21: 610-615 (this issue).
18. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K et al. Status of endothelial dependent vasodilation in patiemnts with hyperuricaemia. Am J Cardiol 2005; 96: 1576-1578.
19. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M et al. Hormonal and cytokine effects of uric acid. Curr Opin Hypertens 2006; 15: 30-33.
20. Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Fontao MJ et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46: 1053-1059.
21. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E et al. Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome? Blood Press 2004; 13: 230-235.
22. Tartan Z, Uyarel H, Kasikcioglu H, Alper AT, Ozay B, Bilsel T et al. Metabolic syndrome as a predictor of non-dipping hypertension. Tohoku J Exp Med 2006; 210: 57-66.
23. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: 1-52.
24. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096-1105.